Boundless Bio Q2 FY26 net loss widens to $23.69 million; operating loss widens to $24.38 million

Reuters2026/08/07 11:06

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Boundless Bio posted a GAAP net loss of $23.69 million for the quarter ended June 30, 2026, widening from $15.68 million a year earlier.
Operating loss widened to $24.38 million from $17.06 million, as total operating expenses climbed to $24.38 million from $17.06 million.
R&D expense rose to $13.97 million from $12.22 million; G&A jumped to $10.41 million from $4.84 million.
The company ended the quarter with $72.6 million in cash, cash equivalents and short-term investments, with no revenue reported.
Boundless Bio entered a merger agreement with Serapha on June 22, expects a $44 million-$48 million pre-closing cash dividend, and cut its workforce by about 75%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Boundless Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-339093), on August 07, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Boundless Bio Q2 FY26 net loss widens to $23.69 million; operating loss widens to $24.38 million

You may also like

Crypto prices